Peptide Therapy Protocols

Overview

Peptide therapy in the context of longevity and regenerative medicine refers to the physician-supervised administration of specific short-chain amino acid sequences — peptides — that interact with defined receptor systems to modulate physiological processes. Unlike systemic hormones that act broadly across multiple organ systems, therapeutic peptides typically bind specific receptors with high selectivity, producing targeted biological effects with comparatively narrow systemic impact.

The peptide therapy landscape is broad, technically complex, and evolving rapidly. It also exists in a complex regulatory environment in the United States — several high-interest peptides have shifted in their FDA status over the 2020s, and patients evaluating peptide protocols must engage with practitioners who can navigate both the science and the regulatory landscape accurately.

Key Peptide Classes in Longevity Medicine

BPC-157 (Body Protection Compound)

BPC-157 is a 15-amino-acid peptide fragment derived from a gastric mucosal protein. It has extensive preclinical research demonstrating accelerated tissue healing — tendon, ligament, bone, nerve, and gut mucosa — through angiogenesis promotion (upregulation of VEGF), fibroblast activation, and modulation of the nitric oxide system. Human clinical data is limited — BPC-157 has not progressed through formal Phase II/III trials for any indication. It is widely used in sports medicine and functional medicine practice on the basis of its preclinical evidence profile. Regulatory status: BPC-157 was removed from the FDA's list of permissible bulk drug substances for compounding in 2023, significantly restricting US availability through licensed pharmacies.

Thymosin Alpha-1 (Tα1)

Thymosin Alpha-1 is a naturally occurring 28-amino-acid thymic peptide with well-documented immunomodulatory activity. It is approved as Zadaxin (SciClone Pharmaceuticals) in over 37 countries for chronic hepatitis B and hepatitis C, as well as immune reconstitution in cancer patients receiving chemotherapy. In longevity medicine, Tα1 is used for immune optimisation — particularly in patients with immune senescence (the age-related decline in immune surveillance and response quality). Unlike BPC-157, Thymosin Alpha-1 has a substantial human clinical evidence base and defined regulatory status in the US as a compounded medication.

Ipamorelin / CJC-1295 (Growth Hormone Secretagogues)

Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist that stimulates pulsatile GH release from the pituitary without significantly elevating cortisol or prolactin — the unwanted effects associated with earlier GHRP compounds. CJC-1295 is a GHRH (growth hormone releasing hormone) analogue that extends the GH-stimulating signal. Combined Ipamorelin/CJC-1295 protocols aim to restore a more youthful pattern of pulsatile GH secretion, supporting lean muscle preservation, fat metabolism, sleep quality, and tissue recovery. These are among the most commonly prescribed peptides in functional longevity medicine. Note: CJC-1295 with DAC (drug affinity complex) is not recommended due to its extremely long half-life creating non-physiological continuous GH stimulation.

Epithalon (Epitalon)

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by the St. Petersburg Institute of Bioregulation and Gerontology as a pineal gland extract derivative. Research from this group — primarily Russian-language literature — suggests telomere-stabilising and anti-aging effects, including upregulation of telomerase activity and modulation of melatonin synthesis. International peer-reviewed evidence is limited. Epithalon is used in longevity medicine circles on the basis of its telomere biology rationale and the published (if geographically narrow) evidence base.

Sermorelin

A 29-amino-acid GHRH analogue (the first 29 amino acids of endogenous GHRH). Sermorelin stimulates the pituitary to produce GH in a physiological, pulsatile fashion. It has FDA approval history as a diagnostic agent for GH deficiency testing. It is less potent than newer secretagogue combinations but has a more established safety profile and greater regulatory clarity. Used in patients with documented GH insufficiency or age-related GH decline.

The Regulatory Landscape

Patients evaluating peptide therapy must understand that the US regulatory environment for peptide compounds is in active flux. FDA actions in 2023–2024 removed several peptides from the Section 503A and 503B bulk drug substance lists, restricting their availability through licensed compounding pharmacies. This includes BPC-157 and several other frequently-used peptides. Practitioners offering these compounds must source through international pharmacies (a legally complex pathway) or work with the reduced set of currently permissible compounds.

Patients should ask any peptide prescriber: what is the current FDA status of each peptide in my protocol, and what is the pharmacy source and quality assurance for the compounded preparation?

Cost in the United States

Monthly peptide therapy costs range from $300–$1,500 depending on the number of peptides in the protocol, the doses used, and the compounding pharmacy. Comprehensive multi-peptide longevity protocols (commonly 2–4 peptides concurrently) range from $600–$1,500/month. Physician consultation, initial lab evaluation, and ongoing monitoring add $500–$2,000/year.

Risks

• Growth hormone side effects: With sustained GH secretagogue use, potential for mild water retention, joint stiffness, carpal tunnel symptoms, and theoretical insulin resistance with very high GH exposure. Cycling protocols minimise receptor desensitisation and GH excess.
• Source quality: The primary risk with compounded peptides is variable purity and concentration from less-regulated sources. Pharmaceutical-grade compounding pharmacy verification is essential.
• Regulatory risk: Prescribing or obtaining removed-from-list compounds creates legal and supply chain risk for both practitioner and patient.